Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 751 - 775 of 14640 in total
Rezafungin is an echinocandin antifungal drug.[A258393,L45633] Unlike other echinocandins such as caspofungin and micafungin, rezafungin has long‐acting pharmacokinetics and a high stability that allows for it to have long dosing intervals maintaining high plasma exposure. Rezafungin has a half-life higher than 130 hours and can be administered once a week...
Approved
Investigational
Matched Description: … _Candida tropicalis_, as well as other _Candida_ and _Aspergillus_ spp. ... Rezafungin has a half-life higher than 130 hours and can be administered once a week instead of daily ... pharmacokinetics and a high stability that allows for it to have long dosing intervals maintaining high …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Fruquintinib is a novel small-molecule anti-VEGFR that targets VEGFR-1,-2, and -3 to inhibit angiogenesis. Tumor angiogenesis is one of the most critical biological processes for increasing oxygen and nutrient supply to cancer cells, and the VEGF/VEGFR pathway is one of the most critical pathways for this phenomenon.[A262102,A262107] Indeed, oncogenic activation,...
Approved
Investigational
Matched Description: … irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate ... Fruquintinib is a novel small-molecule anti-VEGFR that targets VEGFR-1,-2, and -3 to inhibit angiogenesis ... Tumor angiogenesis is one of the most critical biological processes for increasing oxygen and nutrient …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Sotagliflozin is a dual inhibitor of SGLT1 and SGLT2, the first of its kind, which is approved for use in the EU, in combination with insulin, to improve glycemic control in patients with type 1 diabetes mellitus (T1DM) and a BMI ≥27 kg/m2. Its potency in inhibiting SGLT2 is similar...
Approved
Investigational
Matched Description: … Sotagliflozin is a dual inhibitor of SGLT1 and SGLT2, the first of its kind,[A244499] which is approved ... combination with insulin, to improve glycemic control in patients with type 1 diabetes mellitus (T1DM) and ... Its potency in inhibiting SGLT2 is similar to that of other SGLT2 inhibitors, such as [canagliflozin] and
Matched Categories: … Alimentary Tract and Metabolism …
Adalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid arthritis and other chronic debilitating diseases mediated by tumor necrosis factor.[A39984,A39999] It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA. This drug is frequently known as Humira. It is produced...
Approved
Experimental
Matched Description: … a subcutaneously administered biological disease modifier for the treatment of rheumatoid arthritis and ... [A39984,A39999] It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA. ... was approved in July 2022 -,[L42495] adalimumab-bwwd - which was approved in August 2022 -,[L42935] and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Adefovir dipivoxil, previously called bis-POM PMEA, with trade names Preveon and Hepsera, is an orally-administered acyclic nucleotide analog reverse transcriptase inhibitor (ntRTI) used for treatment of hepatitis B. It is ineffective against HIV-1. Adefovir dipivoxil is the diester prodrug of adefovir.
Approved
Investigational
Matched Description: … Adefovir dipivoxil, previously called bis-POM PMEA, with trade names Preveon and Hepsera, is an orally-administered …
Matched Categories: … Nucleosides and Nucleotides ... Nucleoside and Nucleotide Reverse Transcriptase Inhibitors …
An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.
Approved
Investigational
Matched Description: … An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone …
Matched Categories: … Benzamides and benzamide derivatives ... Antineoplastic and Immunomodulating Agents …
Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome.
Approved
Matched Description: … Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. ... treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation[L32519] and
A pyranoquinolone derivative that inhibits activation of inflammatory cells which are associated with asthma, including eosinophils, neutrophils, macrophages, mast cells, monocytes, and platelets.
Approved
Investigational
Matched Description: … are associated with asthma, including eosinophils, neutrophils, macrophages, mast cells, monocytes, and
Matched Categories: … Decongestants and Antiallergics …
Flupentixol is an antipsychotic drug of the thioxanthene group. It exists in two geometric isomers, the trans(E) and pharmacologically active cis(Z) forms. Flupentixol decanoate is one of the active ingredients found in injectable drug formulations: it is produced by esterification of cis(Z)‐flupentixol with decanoic acid. Flupentixol is an antagonist of...
Approved
Investigational
Withdrawn
Matched Description: … [A229083] Flupentixol is an antagonist of both D1 and D2 dopamine receptors. ... It exists in two geometric isomers, the trans(E) and pharmacologically active cis(Z) forms. ... It is approved for use in Canada and other countries around the world, but not in the US. …
A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis.
Approved
Vet approved
Matched Description: … A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. …
Matched Categories: … Antiinflammatory and Antirheumatic Products ... Topical Products for Joint and Muscular Pain ... Antiinflammatory and Antirheumatic Products, Non-Steroids …
Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled substance in the...
Approved
Illicit
Investigational
Withdrawn
Matched Description: … increases the risk of heart attack and stroke in patients with a history of heart disease. ... Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide ... In October 2010, Sibutramine was withdrawn from Canadian and U.S. markets due to concerns that the drug …
Matched Categories: … Alimentary Tract and Metabolism ... Serotonin and Noradrenaline Reuptake Inhibitors ... Norepinephrine, Serotonin, and Dopamine Reuptake Inhibitor Anorectic …
Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin...
Approved
Investigational
Matched Description: … Tolbutamide and its metabolites are excreted in urine (75-85%) and feces. ... It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea ... increase the number and sensitivity of insulin receptors. …
Matched Categories: … Alimentary Tract and Metabolism ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …
A cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action.
Approved
Investigational
Matched Description: … The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic …
Matched Categories: … acebutolol and thiazides ... Beta Blocking Agents and Thiazides ... Beta Blocking Agents, Selective, and Thiazides …
Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients.
Approved
Investigational
Vet approved
Matched Description: … Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and
Matched Categories: … Triazole and tetrazole derivatives ... Metabolic Side Effects of Drugs and Substances ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Difenoxin is a 4-phenylpiperidine which is closely related to the opioid analgesic meperidine. Difenoxin alone is a USA Schedule I controlled drug, as it may be habit forming. However, it is listed as a Schedule IV controlled drug if combined with atropine, which is added to decrease deliberate misuse. Motofen(R)...
Approved
Illicit
Matched Description: … It is approved by the FDA to treat acute and chronic diarrhea. ... Motofen(R) is a brand mixture which combines atropine sulfate and difenoxin hydrochloride. ... It works mostly in the periphery and activates opioid receptors in the intestine rather than the central …
Matched Categories: … Alimentary Tract and Metabolism …
Compound used for therapy of thiamine deficiency. It has also been suggested for several non-deficiency disorders but has not yet proven useful. Fursultiamine is a vitamin B1 derivative.
Approved
Elranatamab is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager. It is a humanized immunoglobulin 2-alanine kappa antibody derived from two monoclonal antibodies (mAbs), an anti-BCMA mAb and an anti-CD3 mAb, each of which contributes one heavy chain and one light chain to drug structure. The resulting 4-chain bispecific...
Approved
Investigational
Matched Description: … immunoglobulin 2-alanine kappa antibody derived from two monoclonal antibodies (mAbs), an anti-BCMA mAb and ... an anti-CD3 mAb,[A261060] each of which contributes one heavy chain and one light chain to drug structure …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers...
Approved
Investigational
Matched Description: … used to detect ALK and ROS1 rearrangements. ... and genetic resistance mechanisms crizotinib is prone to. ... Second- and third-generation ALK-tyrosine kinase-inhibitors have overcome many of the pharmacodynamic …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Celiprolol is indicated for the management of mild to moderate hypertension and effort-induced angina pectoris. It is simultaneously a selective β1 receptor antagonist, a β2 receptor partial agonist and a weak α2 receptor antagonist. In 2010 a clinical trial has suggested a use for this medication in the prevention of...
Approved
Investigational
Matched Description: … Celiprolol is indicated for the management of mild to moderate hypertension and effort-induced angina ... It is simultaneously a selective β1 receptor antagonist, a β2 receptor partial agonist and a weak α2 …
Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017.
Approved
Matched Description: … used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Zytron (DMPA) is under investigation for the treatment and health services research of HIV, Lactation, Contraception, Postpartum Depression, and Immune Cells (Mucosal and Systemic). DMPA has been investigated for the prevention, treatment, and basic science of Weight and Microbiota.
Approved
Investigational
Matched Description: … , Contraception, Postpartum Depression, and Immune Cells (Mucosal and Systemic). ... DMPA has been investigated for the prevention, treatment, and basic science of Weight and Microbiota. ... Zytron (DMPA) is under investigation for the treatment and health services research of HIV, Lactation …
Simethicone is a silicon based surfactant that decreases the surface tension of gastrointestinal gas bubbles to facilitate their elimination. It has a favourable safety profile as it is not systemically absorbed. Simethicone has been in use since the 1940s but was granted FDA approval in 1952.
Approved
Matched Mixtures name: … Gelusil Antacid and Anti-gas …
Potassium perchlorate is an inorganic salt with the chemical formula KClO4. It is a strong oxidizer with the lowest solubility of the alkali metal perchlorates. Potassium is most commonly used in flares and automobile airbags . The use of potassium perchlorate as a component in sealing gaskets for food containers...
Approved
Investigational
Matched Description: … Potassium is most commonly used in flares and automobile airbags [A32609]. ... perchlorate in thyroid disorders has been ceased due to a high risk for developing aplastic anemia and ... Potassium perchlorate acts as a competitive inhibitor of iodine uptake by the thyroid gland and attenuates …
Matched Categories: … Sex Hormones and Insulins …
Rabies virus inactivated antigen, A is an inactivated virus vacine for the intramuscular injection. It is an active immunization against rabies that can be administered pre- or post-exposure to the rabies virus.
Approved
Investigational
Matched Categories: … Immune Sera and Immunoglobulins …
Iptacopan is a small-molecule factor B inhibitor previously investigated as a potential treatment for the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) by inhibiting the complement factor B. Factor B is a positive regulator of the alternative complement pathway, where it activates C3 convertase and subsequently C5 convertase. This is...
Approved
Investigational
Matched Description: … the glycosyl phosphatidylinositol–anchored proteins that normally anchor 2 membrane proteins, CD55 and ... Factor B is a positive regulator of the alternative complement pathway, where it activates C3 convertase and ... , where 82.3% and 77.5% of patients experienced a sustained hemoglobin improvement without transfusions …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Displaying drugs 751 - 775 of 14640 in total